Lymphoma & Plasma Cell Disorders
From the Journals
Improved cancer survival in states with ACA Medicaid expansion
The 2-year overall survival increased from 80.6% before the ACA to 82.2% post ACA in expansion states and from 78.7% to 80% in nonexpansion states...
Diminutio
Dodging potholes from cancer care to hospice transitions
The consequences of suboptimal hospice transitions can damage the mental health and well-being of patient and caregiver.
From the Journals
Few new cancer drugs replace current standards of care
Newer drugs could benefit patients but could increase the cost of care.
Latest News
Ways to lessen toxic effects of chemo in older adults
Three recent high-quality randomized trials evaluated the use of geriatric assessment in older adults with cancer.
Diminutio
Filling opioid prescriptions akin to a Sisyphean task
“Instead of preserving access to desperately needed pain medicine for those suffering with serious illness, states and insurers have aggressively...
From the Journals
Researchers tout new CLL prognostic tool
CLL-CI relies on comorbidity scoring to predict levels of risk linked to survival, time to treatment.
Feature
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
Feature
Convenience, not outcomes may drive robot-assisted surgeries
The sale of robotically assisted surgical devices is expected to reach $14 billion by 2028. The technology is enticing to both surgeons and...
Conference Coverage
Many patients, doctors unaware of advancements in cancer care
“These patients must be spared the traumatic effects of being handed a death sentence that no longer reflects the current reality,” said Dr....
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
News from the FDA/CDC
FDA grants zanubrutinib an accelerated approval in marginal zone lymphoma